27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Die Frühphasen- & R1-Bilder korrelierten signifikant in allen Gruppen (Gesunde: r=0,68-0,84; AD: r=0,81-0,9; PSP-RS: r=0,81-0,86; FTD: r=0,76-0,82). 5 key findings →
Participants: 26 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Sowohl in der Tau- als auch in der Amyloid-PET-Bildgebung zeigte die Quantifizierung eine gute bis exzellente Vorhersage der visuellen Beurteilung (Tau: AUC=0,86, p<0,0001; Amyloid: AUC=0,99, p<0,0001). 5 key findings →
Participants: 201 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Using approximately 5,000 ADNI MRI images, the model achieved 97.67% accuracy, 97.73% precision, 97.67% recall, and 97.65% F1-score, with AUC values near 1.00. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Magnetic Resonance Imaging (MRI) provides detailed structural information, while functional MRI (fMRI) captures temporal brain activity. 2 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Imbalanced medical datasets significantly impair the performance of diagnostic models by biasing predictions towards majority classes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The use of statistical physics models to investigate real-world networks and reveal their underlying dynamics has shown promising results and acquired increasing attention. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) is a progressive neurodegenerative condition that affects the elderly population. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a memory and cognitive function neurodegenerative disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) diagnosis using MRI scans must be very accurate since the subtle differences throughout the course of the disease are difficult to identify. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer’s disease (AD) is an irreversible brain condition that impairs memory and cognitive processes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
5/15 Patient:innen zeigten initial einen visuell negativen Tau-PET Scan zur Baseline, davon konvertierten vier im Follow-up zu einem Tau-positiven Befund. 5 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) is a progressive brain disorder that leads to memory loss and a gradual decline in thinking and reasoning abilities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Effect size analysis proves the fact that the hybrid model produces statistically significant performance, as well as cases of clinically meaningful improvements over lightweight CNN baselines. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Auditory hallucinations in older age could be the first symptom of AD and even occur before cognitive decline. 1 key finding →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer disease (AD) is the leading cause of dementia globally and is defined by the presence of amyloid-β (Aβ) plaques and neurofibrillary tangles formed by the accumulation of phosphorylated tau (p-tau). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Synthetic images were visually consistent, producing plausible negative and positive patterns while preserving continuity in the sagittal plane. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) destroys brain cells and the patient’s memory is lost as a result of a progressive and incurable neurodegenerative disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Bilgisayar destekli cihaz ve sistemlerin sağlık sektöründe giderek artan kullanımı, hastalıkların daha erken ve daha hızlı teşhis edilmesine olanak sağlamaktadır. Bilgisayar destekli sistem ve cihazlar özellikle nörolojik hastalıkların tanı ve görüntülemesinde kritik bir rol oynamaktadır. Merkezi sinir sistemi ve bilişsel fonksiyonların değerlendirilmesindeki gelişmeler, özellikle Alzheimer Hastalığı gibi nörodejeneratif hastalıkların erken teşhisinde önemli avantajlar sağlamaktadır. Çalışmada kullanılan veriler Kaggle platformunda açık kaynaklı olarak bulunan “Augmented Alzheimer MRI Dataset” isimli veri setinden alınmıştır. Bu veri setinde ikinci klasör kullanılmıştır. Toplamda 33.894 adet görüntü bulunmaktadır. Çalışmada Alzheimer hastalığı teşhisi analizi için derin öğrenme sınıflandırıcı model olarak Convolutional Neural Network (CNN) kullanılmıştır. Performans analizi yapılmıştır. Kullanılan CNN model accuracy değerini 0.9102 olarak vermiştir. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The proposed approach achieves 97.9% AD Classification Index (ADCI) for the Kaggle dataset and 97.9% ADCI for the MIRIAD dataset. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer’s disease (AD) is a progressive neurological condition that leads to dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is a neurodegenerative disorder affecting millions globally, with early detection being critical for effective management. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Early detection of Alzheimer's disease is crucial for effective treatment, and the use of brain MRI images has become a common method for diagnosis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is a progressive neurodegenerative disorder that significantly impacts memory, cognition, and daily functioning. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →